Alx Oncology Holdings (ALXO) EBIAT (2019 - 2026)
Alx Oncology Holdings recorded quarterly EBIAT of -$17.9 million in Q1 2026, up 21.54% quarter-over-quarter from -$22.8 million in Q4 2025, and up 41.71% year-over-year from -$12.7 million in Q1 2025.
Alx Oncology Holdings' EBIAT history runs 8 years deep, the most recent figure standing at -$17.9 million for Q1 2026.
- In Q1 2026, EBIAT rose 41.71% year-over-year to -$17.9 million; the TTM figure through Mar 2026 stood at -$88.9 million (up 31.65% YoY), while the FY2025 annual figure was -$101.7 million, up 24.59% from the prior year.
- EBIAT came in at -$17.9 million for Q1 2026 at Alx Oncology Holdings, up from -$22.8 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$17.9 million in Q1 2026 to a low of -$51.0 million in Q3 2023.
- A 5-year average of -$31.7 million and a median of -$30.7 million in 2022 frame the typical range for EBIAT.
- Across the five-year window, EBIAT slumped 102.29% in 2022 and surged 41.71% in 2026, its largest moves.
- Alx Oncology Holdings' EBIAT stood at -$30.7 million in 2022, then sank by 48.07% to -$45.5 million in 2023, then surged by 35.87% to -$29.2 million in 2024, then advanced by 21.65% to -$22.8 million in 2025, then gained by 21.54% to -$17.9 million in 2026.
- According to Business Quant data, EBIAT over the past three periods registered -$17.9 million, -$22.8 million, and -$22.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | -17.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.93 Mn |
| Dec 31, 2025 | -22.85 Mn |
| Sep 30, 2025 | -22.14 Mn |
| Jun 30, 2025 | -25.95 Mn |
| Mar 31, 2025 | -30.75 Mn |
| Dec 31, 2024 | -29.16 Mn |
| Sep 30, 2024 | -30.71 Mn |
| Jun 30, 2024 | -39.40 Mn |
| Mar 31, 2024 | -35.58 Mn |
| Dec 31, 2023 | -45.47 Mn |
| Sep 30, 2023 | -50.99 Mn |
| Jun 30, 2023 | -34.16 Mn |
| Mar 31, 2023 | -30.18 Mn |
| Dec 31, 2022 | -30.71 Mn |
| Sep 30, 2022 | -35.32 Mn |
| Jun 30, 2022 | -32.92 Mn |
| Mar 31, 2022 | -24.53 Mn |
| Dec 31, 2021 | -28.44 Mn |
| Sep 30, 2021 | -24.57 Mn |
| Jun 30, 2021 | -16.27 Mn |
| Mar 31, 2021 | -14.19 Mn |
| Dec 31, 2020 | -18.77 Mn |
| Sep 30, 2020 | -10.18 Mn |
| Jun 30, 2020 | -11.33 Mn |
| Mar 31, 2020 | -5.45 Mn |
| Dec 31, 2019 | -7.76 Mn |
| Sep 30, 2019 | -3.04 Mn |
| Jun 30, 2019 | -4.20 Mn |